<?xml version="1.0" encoding="UTF-8"?>
<ref id="B62-pharmaceuticals-13-00464">
 <label>62.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>McLaughlin</surname>
    <given-names>R.P.</given-names>
   </name>
   <name>
    <surname>He</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>van der Noord</surname>
    <given-names>V.E.</given-names>
   </name>
   <name>
    <surname>Redel</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Foekens</surname>
    <given-names>J.A.</given-names>
   </name>
   <name>
    <surname>Martens</surname>
    <given-names>J.W.M.</given-names>
   </name>
   <name>
    <surname>Smid</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>van de Water</surname>
    <given-names>B.</given-names>
   </name>
  </person-group>
  <article-title>A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy</article-title>
  <source>Breast Cancer Res.</source>
  <year>2019</year>
  <volume>21</volume>
  <fpage>77</fpage>
  <pub-id pub-id-type="doi">10.1186/s13058-019-1161-9</pub-id>
  <pub-id pub-id-type="pmid">31262335</pub-id>
 </element-citation>
</ref>
